Profile of ipilimumab and its role in the treatment of metastatic melanoma

被引：36

作者：

Patel, Sapna P. ^{[1
]}

Woodman, Scott E. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol Dept, Houston, TX 77054 USA

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2011年 / 5卷

关键词：

ipilimumab; melanoma; T-cells; CTLA-4; T-LYMPHOCYTE ANTIGEN-4; PHASE-II; TUMOR-REGRESSION; IV MELANOMA; STAGE-III; CTLA-4; BLOCKADE; AUTOIMMUNITY; INTERLEUKIN-2; THERAPY;

D O I：

10.2147/DDDT.S10945

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Melanoma is an immunogenic cancer. However, the ability of the immune system to eradicate melanoma tumors is affected by intrinsic negative regulatory mechanisms. Multiple immune-modulatory therapies are currently being developed to optimize the immune response to melanoma tumors. Two recent Phase III studies using the monoclonal antibody ipilimumab, which targets the cytotoxic T-lymphocyte antigen (CTLA-4), a negative regulator of T-cell activation, have demonstrated improvement in overall survival of metastatic melanoma patients. This review highlights the clinical trial data that supports the efficacy of ipilimumab, the immune-related response criteria used to evaluate clinical response, and side-effect profile associated with ipilimumab treatment.

引用

页码：489 / 495

页数：7

共 44 条

[1] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].

Adjei, Alex A. ;

Cohen, Roger B. ;

Franklin, Wilbur ;

Morris, Clive ;

Wilson, David ;

Molina, Julian R. ;

Hanson, Lorelei J. ;

Gore, Lia ;

Chow, Laura ;

Leong, Stephen ;

Maloney, Lara ;

Gordon, Gilad ;

Simmons, Heidi ;

Marlow, Allison ;

Litwiler, Kevin ;

Brown, Suzy ;

Poch, Gregory ;

Kane, Katie ;

Haney, Jerry ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146

[2]

[Anonymous], 2007, ONE MONTH INTRAVENOU

[3]

[Anonymous], IMMUNE MEDIATED ADVE

[4] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[5] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[6] Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients [J].

Besser, Michal J. ;

Shapira-Frommer, Ronnie ;

Treves, Avraham J. ;

Zippel, Dov ;

Itzhaki, Orit ;

Hershkovitz, Liat ;

Levy, Daphna ;

Kubi, Adva ;

Hovav, Einat ;

Chermoshniuk, Natalia ;

Shalmon, Bruria ;

Hardan, Izhar ;

Catane, Raphael ;

Markel, Gal ;

Apter, Sara ;

Ben-Nun, Alon ;

Kuchuk, Iryna ;

Shimoni, Avichai ;

Nagler, Arnon ;

Schachter, Jacob .

CLINICAL CANCER RESEARCH, 2010, 16 (09) :2646-2655

[7] KIT as a Therapeutic Target in Metastatic Melanoma [J].

Carvajal, Richard D. ;

Antonescu, Cristina R. ;

Wolchok, Jedd D. ;

Chapman, Paul B. ;

Roman, Ruth-Ann ;

Teitcher, Jerrold ;

Panageas, Katherine S. ;

Busam, Klaus J. ;

Chmielowski, Bartosz ;

Lutzky, Jose ;

Pavlick, Anna C. ;

Fusco, Anne ;

Cane, Lauren ;

Takebe, Naoko ;

Vemula, Swapna ;

Bouvier, Nancy ;

Bastian, Boris C. ;

Schwartz, Gary K. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22) :2327-2334

[8] Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells [J].

Chambers, CA ;

Sullivan, TJ ;

Allison, JP .

IMMUNITY, 1997, 7 (06) :885-895

[9] PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors [J].

Curran, Michael A. ;

Montalvo, Welby ;

Yagita, Hideo ;

Allison, James P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) :4275-4280

[10] Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade [J].

Downey, Stephanie G. ;

Klapper, Jacob A. ;

Smith, Franz O. ;

Yang, James C. ;

Sherry, Richard M. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Hughes, Marybeth S. ;

Allen, Tamika E. ;

Levy, Catherine L. ;

Yellin, Michael ;

Nich, Geoffrey ;

White, Donald E. ;

Steinberg, Seth M. ;

Rosenberg, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6681-6688

← 1 2 3 4 5 →